Stephen P. Fitzgerald
Nigel G. Bean3†
Henrik Falhammar- 1The Departments of General Medicine and Endocrinology, The Royal Adelaide Hospital, Adelaide, SA, Australia
- 2School of Medicine, The University of Adelaide, Adelaide, SA, Australia
- 3Adjunct Professor, School of Mathematical Science, University of Adelaide, Adelaide, SA, Australia
- 4Department of Obstetrics and Gynaecology, The Townsville Hospital, Townsville, QLD, Australia
- 5School of Medicine, University of Queensland, St Lucia, QLD, Australia
- 6Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden
- 7Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Recently proposed concepts regarding the nature and assessment of the thyroid state have provided a model more consistent with empiric evidence. It now appears likely that there are no such entities as thyroid set points and individual euthyroidism. Rather than there being discrete thyroid states, peripheral organ parameters are associated with thyroid function in a continuous manner. Thyroid hormone levels and, in particular, levels of free thyroxine now appear to be superior to thyrotropin levels as indicators of the thyroid state. Complicating the assessment of the correlations of the thyroid state with pregnancy outcomes are the contribution of the placenta to maternal thyroid function, fetal thyroid development, the multiple potential pathways to any particular outcome, the likely presence of small critical periods of time, the differing genetics of fetal and maternal tissues, and the unreliability of thyroid hormone assays. Nevertheless, there is no apparent reason for there to be a change in pregnancy to the basic principles of thyroid hormone action. The relationships between mild abnormalities of the thyroid state and pregnancy outcomes and the value of treating such mild abnormalities remain uncertain and controversial. The evidence suggests that further investigation of these clinical questions might better be based on thyroid hormone, particularly free thyroxine, levels. In the investigation of borderline low thyroid states, the categories of subclinical hypothyroidism and isolated hypothyroxinemia might both be abandoned with attention being directed to low free thyroxine levels regardless of the thyroid-stimulating hormone (TSH) levels. For these changes to occur, there would ideally be improvements in the assays for free thyroxine in pregnancy. The evidence suggests that, just as in the non-pregnant situation, pregnancy guidelines based on thyrotropin levels may need revision.
Introduction
Recent clinical evidence (1–3) has indicated that developments in the understanding of thyroid physiology (4–7) have implications for clinical thyroid medicine and thyroid research (8). In brief, the suggested conceptual changes are that clinical parameters associate in a continuous manner with thyroid function even throughout the normal range (3), that there are no such entities as thyroid hormone set points and “individual euthyroidism” (5), and that clinical parameters are more likely to be associated with thyroid hormone, particularly free thyroxine (FT4), levels than with thyrotropin (TSH) levels (1) such that the thyroid state of an individual is better judged biochemically by FT4 levels rather than TSH levels. It follows that subclinical thyroid dysfunction is not an accurate guide to the thyroid state of peripheral tissues and that trials of treatment of mild thyroid dysfunction might best be addressed at restoring FT4 levels rather than TSH levels (8).
Most of the research underpinning the above concept has focused on the non-pregnant state. Nevertheless, the meta-analysis of the associations of clinical parameters with the different thyroid function tests did include pregnancy outcomes, and the relevant results were identical to other clinical parameters in that FT4 levels, as compared with TSH levels, were more often associated with outcomes (1).
Though there is evidence to suggest that some of the associations between mild thyroid dysfunction and clinical outcomes are on the basis of causation, there is no convincing evidence that treatment of mild thyroid dysfunction is effective (9, 10). This is true for both pregnancy- and non-pregnancy-associated outcomes (11–13). Trials of treatments thus far may have been flawed however in that the vast majority have selected subjects on the basis of subclinical thyroid dysfunction and directed treatments to TSH levels rather than FT4 levels. Nevertheless, at least some of the associations may result from reverse causation or bidirectional causation (14) in which case the prospects of deriving benefit from treatment are reduced.
The approach to thyroid dysfunction in pregnancy may even be more controversial than in the non-pregnant state. For example, much thyroid/pregnancy research has been devoted to the associations of subclinical thyroid dysfunction with hypertensive disorders of pregnancy and (pre)eclampsia (15, 16), but a recent review of preeclampsia from a non-endocrinology center did not even mention thyroid dysfunction (17). On account of the relevant studies being negative or conflicting (12, 18, 19), national colleges of obstetrics do not consider subclinical thyroid dysfunction to be a relevant entity (20, 21). Nevertheless, increasing numbers of pregnant women are having thyroid treatments (22) presumably in part on account of guidelines (23–25) and some positive trials concerning both associations of subclinical hypothyroidism with pregnancy outcomes and treatment of the thyroid state (26–29).
Though our meta-analysis (1) did suggest that the new concepts and principles apply similarly to pregnant women, thyroid physiology of the pregnant state is more complex than in the non-pregnant state. Furthermore, a recent meta-analysis of thyroid function test associations with preeclampsia has suggested that there is a greater association with TSH levels than with FT4 levels (16). Here, we review and analyze the current state of the literature with regard to the extrapolation of the new general principles of assessment of the thyroid state to pregnant women.
Physiology/pathophysiology
In the non-pregnant state, the outline of physiology is relatively simple in that the thyroid gland secretes thyroid hormones in response to TSH and these hormones feedback negatively on pituitary TSH secretion. Subsequently, clinical parameters may or may not be influenced by the levels of the thyroid hormones. The details of this system, e.g., receptor and deiodination physiology modulating local actions of thyroid hormones (30), add a layer of complexity as do the possibilities that TSH itself may influence some peripheral tissue physiological processes (31, 32) and that some peripheral tissues may modulate TSH secretion (introducing reverse or bidirectional causation) (14).
In pregnancy, the physiology is more complicated. The basic outline of maternal thyroid regulation is directly affected by the placenta via the secretion of human chorionic gonadotropin (hCG) (33) and probably too by other substances including antiangiogenic factors, particularly soluble fms-like tyrosine kinase-1 (sFlt1) (16). Although the thyrotrophic potency of hCG is low compared to TSH, high levels of hCG as seen in the first trimester result in significant thyroid stimulation (34). Later in pregnancy, hCG levels fall as do thyroid hormone levels (which drop below baseline) (35). The rises in total T4 (TT4) resulting from pregnancy-induced changes to hepatic stimulation of thyroid-binding globulin (TBG), albumin, and other proteins are more apparent than any rises in free thyroid hormones (35). The precise quantification of FT4 levels is however limited in pregnancy by assay performance (23, 36, 37). Multiple pregnancy, particularly in association with assisted reproductive technology, results in greater increases in hCG levels and thyroid stimulation as compared with singleton pregnancies (38). Furthermore, the placenta in abnormal conditions may secrete abnormal (15, 39), more potent forms of hCG in terms of thyroid stimulation.
The fact that thyroid hormone levels may be affected by placental function introduces the possibility of reverse causation, i.e., associations of any pregnancy parameters with the thyroid status may be by virtue of the thyroid hormone level and the parameter both being consequences of placental function (34). There is in fact empiric evidence (albeit conflicting) suggesting direct relationships between hCG levels and pregnancy outcomes (15, 40, 41). Potentially, there may be bidirectional influences, e.g., placental function may be influenced by the thyroid state and vice versa. Perhaps the initial influence is exerted by the preconception thyroid state (42).
The relationships between thyroid function and pregnancy outcomes may also be subject to confounding. For example, antibody positivity may affect thyroid function in pregnancy (43), but pregnancy outcomes may also be affected by antibody actions unrelated to any effect on thyroid function (23, 26).
In early pregnancy, there is increased iodine intake requirement on account of increased urinary iodine clearance (44) related to increased renal plasma blood flow and glomerular filtration (45). Throughout pregnancy, iodine is shifted from the maternal circulation to the fetal–placental unit (44). Iodine deficiency results in changes to thyroid function and maternal goiter or thyroid enlargement (46, 47). In turn, the changes to thyroid function in pregnancy are believed to be a cause of any related impairment of fetal neurological development (48). However, the evidence for this being the only mechanism at play is inconsistent (49), and it may be that deficits are more related to the iodine status than the thyroid status (50). Obesity, iron deficiency, and toxic chemicals may also result in changes to thyroid function in pregnancy and potentially might also have direct influences on pregnancy outcomes (37) . In these circumstances, the thyroid function may be a marker of the factors influencing pregnancy outcome, and correction of the thyroid state would not be expected to be therapeutic.
The assessment of the relationship between thyroid function and clinical parameters is also complicated by the fact that different pathophysiologies with different relationships to thyroid function may result in the same clinical parameter. This potentially can occur in non-pregnant and pregnant individuals. For example, high levels of thyroid hormones may directly increase the risk of atrial fibrillation (3), while low levels might increase the risk via an association with obesity (51). In pregnancy, preeclampsia, for example, might be related to low thyroid hormone-related endothelial cell dysfunction associated with decreased production of vasoactive substances (16, 52) or to high thyroid hormone-related endothelial cell dysfunction associated with impairment of mechanisms protective against endothelial damage (16, 53).
The opportunity for such multiple pathways increases in pregnancy given that the thyroid state can predispose to an outcome via direct effects on the fetus, via direct effects on the placenta, and/or indirectly via maternal effects (54). Possible examples include infant IQ that might be compromised directly by low thyroid hormone levels and by high thyroid hormone level-related placental dysfunction.
There may be critical periods during pregnancy where outcomes (37) and treatments (55) are sensitive to the thyroid status. Studies that miss these time points may potentially miss the relevant outcome (56). Studies in non-pregnant individuals are not so timing-dependent.
In pregnancy, apart from the complication of placental effects on maternal thyroid function, there is the complication of the presence of two thyroids, i.e., the fetal and maternal thyroids. It is quite possible that as well as there being placental effects on maternal thyroid function, there is control of fetal thyroid function by maternal thyrotrophin-releasing hormone (TRH) (54, 57). In these circumstances, low maternal thyroid function could conceivably lead to increased fetal thyroid function via higher TRH levels. Both the capacity of the fetal thyroid and the timing of its onset of function sometime in the second trimester (54, 58) potentially affect any outcome related to the maternal thyroid status. Prior to the maturation of fetal thyroid production, the FT4 that reaches the fetal brain is all of maternal origin (54, 58). The quantity of this FT4 is small, most FT4 (and FT3) having been deiodinated in the placenta (54, 59). This contrasts with the end of pregnancy when circulating fetal thyroid hormones are a mixture of hormones from the maternal and fetal thyroid glands (54).
The thyroid status of the placenta may not be a simple concept, with there being evidence that placental exposure to thyroid hormones may not be uniform with the maternal placenta being exposed to greater levels than the fetal placenta (59).
Thus, though maternal tissues, the maternal placenta, the fetal placenta, and the fetus are likely to have intracellular thyroid hormone levels related to the maternal circulating levels of thyroid hormones, this relationship is more complicated than in the circumstances of considering outcomes in non-pregnant individuals.
The complexity of the causation of the outcomes in pregnancy, and the multiplicity of tissue thyroid states to consider, may contribute to the conflicting results of associations of pregnancy outcomes with hormonal status while obscuring any potential intervention targets.
Free thyroxine (FT4), thyroid-stimulating hormone (TSH), or total thyroxine (TT4) to assess the thyroid state in pregnancy
We have indicated that, in general, FT4 is the better indicator of the thyroid state of peripheral tissues (1). In our meta-analysis, FT4 performed better in all examined clinical parameters including death (1). Groothof et al. (2) confirmed this latter finding. There was evidence that at least some of the associations we observed were causal, these being the only associations that logically can be used to assess the thyroid state. We noted that even in the conservative circumstances of none of the associations being causal, there remained no evidence for the superiority of TSH. Our meta-analysis findings for pregnancy-related outcomes were similar to those for other parameters, but relatively few pregnancy studies were included (1).
At the most fundamental level, the physiology of thyroid hormone levels does not change with pregnancy. Thyroid hormone and TSH levels are determined by the thyroid hormone (principally FT4)/TSH feedback loop. The evidence indicates that the levels represent balance points of the physiological processes at play rather than the previous concept that the levels are genetically set and physiological processes act to defend these levels (5). The changes in pregnancy concern the limbs of the feedback loop, i.e., the details change. In particular, in pregnancy, the thyroid curve, the description of the FT4 response to TSH stimulation (7), changes in that on account of hCG, higher FT4 levels are seen for any level of TSH. The fundamental principle as to the derivation of the balance point for thyroid function tests and thereby the conclusion that FT4 is the better guide to the thyroid state is not affected by such changes.
It has also been previously thought that the genetically determined “set-point” of thyroid hormones of each individual represented an optimum level for the individual (7). It followed from this that on account of the sensitivity of TSH levels to primary changes in thyroid hormone levels, TSH levels were the best guide to any deviation from the individual set point and thereby the best guide to the thyroid state of peripheral tissues (60). The evidence now indicates that as well as the concept of such a set point being flawed (5), all levels of thyroid hormones within the normal range are associated with risks and benefits (61). Thus, though TSH levels may provide evidence of a change in thyroid function, there is no rationale to consider such a change to be necessarily disadvantageous, and though TSH levels may provide prognostic information, there is no reason to consider them to be the best guide to the thyroid state of peripheral state in general (8, 61). As a maternal TSH level thereby cannot be assumed to be the best biochemical marker of the thyroid state of even maternal tissues, it is difficult to sustain the argument that a maternal TSH level can be the best marker of the thyroid state of maternal and placental/fetal tissues given that they have different DNA and thereby potentially different sensitivities to thyroid hormones and different physiologies.
T4 is found in coelomic fluid in early pregnancy in proportion to maternal levels (58) and the placenta is impermeable to TSH (54). It follows that it is likely that the placenta and the fetus respond to an FT4 level regardless of the maternal TSH level. It is therefore likely that, notwithstanding the complexities of pregnancy physiology, levels of maternal FT4 are the better markers of the thyroid state of the mother and the placenta/fetus. As there exist physiological processes that act to minimize interindividual and intraindividual thyroid hormone level deviation from levels around the middle of the population range, and pathology tends to increase with such deviations, it is likely that optimum levels are likely to be mid-range (62, 63).
The recent meta-analysis by Toloza et al. (16) suggested a better relationship of a clinical parameter, preeclampsia, with TSH levels as compared with FT4 levels. Previous such studies of pregnant women, however, have shown similar but inverse relationships with FT4 and TSH (64, 65), and abnormally low TSH levels in the presence of normal FT4 levels (subclinical hyperthyroidism) are not associated with the pregnancy risks seen with elevated levels of thyroid hormones (overt hyperthyroidism) (66).
In pregnancy, therefore, we have conflicting studies both in terms of outcomes and in terms of the relative association with TSH or FT4 with these outcomes in the context of a lack of strong evidence as to whether the nature of any association is causal due to reverse causation or due to another mechanism.
On theoretical physiological grounds, TSH was previously thought to be the best indicator of the thyroid state. We have indicated above that now the physiological evidence would favor FT4.
On the other hand, there are problems with most if not all FT4 assays in pregnancy (23, 36, 37). FT4 represents only about 0.03% of circulating TT4. The challenges of measuring this small fraction increase in pregnancy on account of the increases in circulating levels of TBG, nonesterified fatty acids, and the decrease in circulating levels of albumin (23, 37). There is poor correlation between the readily available immunoassays, and even equilibrium dialysis and ultrafiltration followed by liquid chromatography and spectrometry have technical and practical limitations for use in pregnancy (37). The use of the FT4 index as a measure of FT4 may be superior, but this test is not widely available (37). There are recommendations to use trimester-specific, method-specific, and locally derived ranges. This latter suggestion may be impractical (23). These problems with the FT4 assay in pregnancy may blunt any associations with FT4 while sparing the associations with TSH. That is, any better relationship with TSH may be artifactual. In these circumstances, it may be pragmatic to prefer the TSH level even though strictly speaking any relationship might be stronger with the true FT4 level.
In addition, if indeed a relationship between thyroid function is a result of reverse or bidirectional causation, TSH may have a better association with an outcome than FT4 levels. An example of such might be if there were a causal relationship between low thyroid function and a parameter and, at the same time, a reverse relationship by which the parameter (perhaps as a compensation) stimulated thyroid function via the stimulation of TSH. In these circumstances, on account of the initial causation, the parameter would initially be associated with low FT4 levels and high TSH levels, the association with the high TSH levels being on account of the inverse correlation in the population between FT4 levels and TSH levels (67). The reverse causation relationship however would subsequently raise the TSH levels and thereby the FT4 levels. In this situation, the initially high TSH levels have been pushed higher but the initially low FT4 levels are not so low and thus the relationship has become stronger with TSH levels. The associations of obesity with TSH and FT4 levels may be an example of this type of bidirectional causation (14). The study by Toloza et al. (16) is potentially a similar example as again the relationship demonstrated, between thyroid function and gestational hypertension/preeclampsia, concerned a relationship with low thyroid function.
Any relationship of an outcome with TSH might also potentially result from a relationship between TSH and any other parameter, e.g., hCG (34, 40, 41) or thyroid antibodies (23, 43, 68), that affects outcomes. If such a relationship was stronger than the corresponding relationship with FT4, the relationship between TSH levels and outcomes might be stronger than the relationship between FT4 and outcomes. In these circumstances, the better relationship with TSH would be an example of confounding.
Finally, a stronger association with TSH might be seen should TSH directly act on placental or fetal tissues. In the non-pregnant state, this phenomenon has been recognized. TSH has been reported to have effects on the heart (31) and on bone (32) independently of any effects mediated by TSH as an indicator of the thyroid state.
Despite the problems with FT4 assays and the possible causes of spurious TSH relationships, there are studies that report superior relationships with FT4 (68–71). There are fewer opportunities for such superiority of FT4 to be spurious.
It has been suggested that the use of TT4 with mathematical adjustment of the range to take into account the increase in TBG may be superior or an alternative to the use of FT4 in pregnancy (23, 37). For most of pregnancy, TT4 levels are 50% above baseline (23, 37). There are however disagreements regarding the detail of any such mathematical adjustments (72). There are also theoretical problems with this suggestion. In the first instance, a major factor determining the changes in the thyroid hormone-binding globulin, and thereby the TT4 level in pregnancy, is the placenta via the production of estrogen (73). Thus, the previously mentioned possibility of reverse causation of pregnancy parameters related to the placental production of hCG is amplified. That is, pregnancy outcomes and TT4 levels may result from placental function rather than the pregnancy outcomes being a consequence of the TT4 levels. In an individual case, the FT4 proportion of TT4 would be uncertain. The use of TT4 rather than FT4 contradicts the “free hormone hypothesis” that is thought likely to apply to thyroid hormones (as well as to sex steroids, glucocorticoids, and vitamin D) (74, 75). Furthermore, the modern studies looking at correlations of clinical parameters, including those related to pregnancy, with the thyroid status have relied on FT4 levels (37), and it is not known whether or not such correlations can be extrapolated to TT4 levels.
We have previously indicated that although clinical parameters appear to associate most robustly with FT4 levels, free and total T3 levels also associate with these parameters more often than do TSH levels and that further studies to determine the idiosyncrasies of each organ/tissue are indicated (61). Analogously, in the perhaps unlikely circumstances that TT4 levels were found to be the best guide to the pregnancy thyroid state, the fundamental principle would remain that thyroid hormone measurement is preferable to TSH measurement.
Synthesis and conclusions
Ideally, studies of associations of clinical parameters with thyroid function tests would indicate the best test of the thyroid state relevant to the parameter, and ideally, the relationship between the thyroid state and the parameter would be causal and potentially amenable to intervention. Furthermore, it would be simpler if the relationship between the thyroid function and the parameter was in one direction only. One would then hope that follow-up intervention studies would have positive results, confirming the causal nature of the associations and the value of therapy.
With regard to the non-pregnant state, there is now a model of physiology coherent with empirical data (61). There is good evidence that FT4 is generally superior to TSH in defining the thyroid state, and there would appear to be good prospects for proceeding with new intervention trials using FT4 levels for subject selection and treatment targets. In particular, the associations in older individuals OF atrial fibrillation, dementia, and death WITH FT4 levels, apparently satisfying the above conditions, appear ripe for intervention studies. Notably, these associations concern FT4 levels at the upper end of the range. The nature of the associations at the lower ranges of thyroid function, where the impetus to treat in pregnancy lies, seems less clear.
The field of the association of the thyroid state with pregnancy-related outcomes appears to be less advanced and more conflicted. Consequently, many of the recommendations in the guidelines are weak or based on a modest evidence base (23–25). This state may be a result of the greater complexity of thyroid function associations with outcomes in pregnancy. Any state of thyroid abnormality may be a heterogeneous group of diseases (37), only some of which might benefit from thyroid function manipulation alone. It seems that we need more studies of the kind published by Korevaar et al. (15) in which a more wholistic view of thyroid physiology was employed, the analysis encompassing clinical parameters, indices of thyroid function and hCG. It may be too that such studies also need to consider other factors such as preconception indices of thyroid function (42), iodine status, and antibody status.
Our general conclusions regarding the implications of the recently introduced concepts of thyroid action and measurement included recommendations that the thyroid state be assessed on the basis of FT4 levels rather than TSH levels and that subclinical hypothyroidism not be regarded as an accurate measure of the thyroid state of peripheral tissues (8, 61). We have indicated that borderline low thyroid function is reflected in a borderline low FT4 level regardless of the TSH level. Isolated hypothyroxinemia, which may be a mild form of secondary hypothyroidism (76), then becomes a subset of borderline low thyroid function that also includes a subset of subclinical hypothyroidism. These conclusions conflict with the various current guidelines regarding diagnosis, monitoring, and treatment in pregnancy that are based on TSH levels (23–25).
There are no apparent reasons for the fundamental general principles of thyroid physiology not to hold in pregnancy, and the patchy empirical evidence does not indicate the state of pregnancy to be exceptional in this regard. It follows that, analogously to those pertaining to the non-pregnant state, all of the current guidelines, which differ in detail but are based on identical principles, may be flawed. Any true relationships between either or both TSH and subclinical thyroid dysfunction and clinical outcomes are likely to be indirect, reflecting the population correlation of TSH with FT4 (67). Otherwise, relationships may result from the opportunities for artifact, confounding, reverse causation, and bidirectional effect. If mild thyroid dysfunction truly affects pregnancy and fetal outcomes, diagnosis and treatment on the basis of FT4 levels are likely to be more effective than relying on TSH levels.
The largely negative trials to date performed in non-pregnant individuals on the basis of TSH levels confirm the impression that such subject selection criteria and treatment targets are less than optimal (9, 10). The few positive studies in pregnancy largely involve antibody-positive women and are difficult to interpret mechanistically (23). It is difficult to separate any effects of treating the low thyroid state per se from any non-specific/pharmacological effects of thyroxine supplementation particularly in antibody-positive women. Though it has been proposed that the negative effect of thyroid antibodies on hCG stimulation of thyroid function provides a potential mechanism for the link between thyroid antibodies and pregnancy outcomes (43), this logic would imply similar outcomes in individuals with similar thyroid hormone levels in the absence of antibodies. New trials of different designs appear indicated. These may depend on the more sophisticated understanding of the associations between thyroid function and pregnancy outcomes suggested above.
It may be, that though apparently safe (77), intervening in cases of borderline thyroid dysfunction in pregnancy, however defined, offers modest or even no benefit (11, 12, 20, 21). In these circumstances, the definition of borderline thyroid dysfunction in pregnancy would have limited clinical importance. If this could be clearly demonstrated, clinicians and researchers could direct their attention elsewhere.
On the other hand, there are studies of isolated hypothyroxinemia that do suggest that borderline low thyroid function may have significant associations with placental abruption (13), spontaneous premature delivery (68), and perhaps most likely with disorders of fetal neurodevelopment (37, 78). Inconsistent definition of borderline thyroid dysfunction and the timing of testing and intervention may have contributed to this conflict in results (37, 56). Furthermore, animal data suggest that the association of hypothyroxinemia and abnormal fetal neurodevelopment is causal (54) and treatable (55). These conclusions are not so strong for humans (11, 54).
Regardless of the relevance of borderline low thyroid function to pregnancy outcomes, there is at this stage no apparent physiological reason or empiric evidence justifying the continued TSH level approach to classifying and managing the thyroid state in pregnancy. If anything, TSH levels would appear to be less accurate in pregnancy than in the non-pregnant state. Thyroid hormone levels and, in particular, FT4 levels would appear to be more accurate.
Although there are already studies supporting the superiority of FT4 levels in the diagnosis of the thyroid state in pregnancy (68–71), a more accurate assay for FT4 in pregnancy would likely aid a shift in emphasis from TSH levels to FT4 levels. In the absence of such an assay, it may be necessary in some circumstances to continue to use TSH levels for pragmatic reasons and advancement in thyroid/pregnancy research may be limited. Perhaps, previously, the need for an accurate measurement of FT4 in pregnancy was not thought to be so pressing given that TSH was thought to be the best guide to the thyroid state. One recommendation following the changing concepts regarding the thyroid state might therefore be to further research FT4 assays in pregnancy. Failing this, the value of TT4 measurement might be explored further.
In conclusion, our review found that despite much work, there is not clarity in the current status of the interaction of thyroid function (and in particular borderline low thyroid function) with pregnancy outcomes. The physiological models and empiric evidence are not mutually coherent. These deficiencies may originate in part from the fundamental emphasis on TSH levels in the assessment of the peripheral thyroid state. We found no reasons to consider that in pregnancy, the conceptual changes regarding the nature of, and the general assessment of, the thyroid state do not apply. By extension, the clinical and research implications for pregnancy might parallel the general implications (8) and include deemphasizing arbitrary categories, and in particular the concepts of subclinical hypothyroidism and isolated hypothyroxinemia, with a switch of emphasis to FT4 levels as a continuum, regardless of TSH levels.
In pregnancy, the complex physiology/pathophysiology and the difficulties of obtaining an accurate measurement of FT4 complicate the application of these implications.
Author contributions
STF Conceived paper, wrote initial draft. NB provided mathematical support, revised the draft. SAF collaborated with review of obstetric physiology/fetal development. HF revised draft substantially. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Fitzgerald SP, Bean NG, Falhammar H, Tuke J. Clinical parameters are more likely to be associated with thyroid hormone levels than with TSH levels: A systematic review and meta-analysis. Thyroid (2020) 30(12):1695–709. doi: 10.1089/thy.2019.0535
2. Groothof D, Flores-Guerrero JL, Noble IM, Bouma HR, Gruppen EG, Bano A, et al. Thyroid function and all - cause and cardiovascular mortality: A population-based cohort study. Endocrine (2021) 71:385–96. doi: 10.1007/s1202-020-02397-z
3. Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC, et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation (2017) 136(22):2100–16. doi: 10.1161/CIRCULATIONAHA.117.028753
4. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Recent advances in thyroid hormone regulation: Toward a new paradigm for optimal diagnosis and treatment. Front Endocrinol (2017) 8:364. doi: 10.3389/fendo.2017.00304
5. Fitzgerald SP, Bean NG, Fitzgerald LN. Population data indicate that thyroid regulation is consistent with an equilibrium- point model, but not with a set point model. Temperature (2017) 4:114–6. doi: 10.1080/23328940.2017.1281370
6. Fitzgerald SP, Bean NG. The relationship between population T4/TSH set point data and T4/TSH physiology. J Thyroid Res (2016) 2016:6351473. doi: 10.1155/2016/6351473
7. Dietrich JW, Landgrafe G, Fotiadou EH. TSH and thyrotropic agonists: key actors in thyroid homeostasis. J Thyroid Res (2012) 2012:351864. doi: 10.1155/2012/351864
8. Fitzgerald SP, Bean NG, Hennessey JV, Falhammar H. Thyroid paradigm switch from thyrotropin to thyroid hormones - future directions and opportunities in clinical medicine and research. Endocrine (2012) 74(2):285–289. doi: 10.1007/s12020-021-02851-6
9. Villar HC, Sacconato H, Valente O, Atallah AN. Thyroid hormone for subclinical hypothyroidism. Cochrane Database Syst Rev (2007) 18:CD003419. doi: 10.1002/14651858CD003419.pub2
10. The TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med (2017) 376:2534–44. doi: 10.1056/NEJMoa1603825
11. Lazarus JH, Bestwick JP, Channon S, Paradice R, Maina A, Rees R, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med (2012) 366(6):493–501. doi: 10.1056/NEJMoa1106104
12. Casey BM. Effect of treatment of maternal subclinical hypothyroidism or hypothyroxinemia on IQ in offspring. Abstract S2 Am J Obstetrics Gynaecology (2015) 214 S2:815–25. doi: 10.1016/j.ajog.2015.10023
13. Chan S, Boelaert K. Optimal management of hypothyroidism and euthyroid TPO antibody positivity preconception and in pregnancy. Clin Endocrinol (2015) 82:313–26. doi: 10.1111/cen.12605
14. Rotondi M, Magri F. Chiovato l thyroid and obesity: not a one-way interaction. J Clin Endocrinol Metab (2011) 96:344–346F. doi: 10.1210/jc.2010-2515
15. Korevaar TIM, Steegers EAP, Chaker L, Medici M, Jaddoe VWV, Visser TJ, et al. The risk of preeclampsia according to high thyroid function in pregnancy differs by hCG concentration. J Clin Endocrinol Metab (2016) 101(12):5037–43. doi: 10.1210/jc.2016-2397
16. Toloza FJK, Derakhshan A, Männistö T, Bliddal S, Popova PV, Carty DM, et al. Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: A systematic review and individual-participant data meta-analysis. Lancet Diabetes Endocrinol (2022) 10(4):243–52. doi: 10.1016/S2213-8587(22)00007-9
17. Magee LA, Nicolaides KH, von Dadelzzen P. Preeclampsia. N Engl J Med (2022) 386:1817–32. doi: 10.1056/NEJMMrs2109532
18. Casey BM, Dashe JS, Spong CY, McIntire DD, Leveno KJ, Cunningham GF. Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. Obstet Gynecol (2007) 109(5):1129–35. doi: 10.1097/01.AOG.0000262054.03531.24
19. Sheehan PM, Nankervis A, Araujo Júnior E, Da Silva Costa F. Maternal thyroid disease and preterm birth: Systematic review and meta-analysis. J Clin Endocrinol Metab (2015) 100(11):4325–31. doi: 10.1210/jc.2015-3074
20. RANZCOG. Subclinical hypothyroidism and hypothyroidism in pregnancy (C-obs 46). 1 Bowen Crescent, Melbourne, Victoria, Australia:RANZCOG (2022).
21. Thyroid disease in pregnancy. Obstetrics Gynecology (2020) 135(6):e261–74. doi: 10.1097/AOG.0000000000003893
22. Bakken KS, Nermo KR, Nedrebø BG, Korevaar TIM, Strand TA. Antenatal thyroid hormone therapy and antithyroid drug use in Norway from 2004 to 2018. Endocr Connect (2022) 11(4):e210631. doi: 10.1530/EC-21-0631
23. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid (2017) 27:315–89. doi: 10.1089/thy.2016.0457
24. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European Thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J (2014) 3(2):76–94. doi: 10.1159/000362597
25. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of thyroid dysfunction during pregnancy and postpartum: An endocrine society clinical practice guideline. J Clin Endocrinol Metab (2012) 97(8):2543–65. doi: 10.1210/jc.2011-2803
26. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: Effects on obstetrical complications. J Clin Endocrinol Metab (2006) 91(7):2587–91. doi: 10.1210/jc.2005-1603
27. Yuan N, Sun J, Zhao X, Du J, Nan M, Zhang Q, et al. Untreated thyroid autoantibody-negative SCH increases the risk of spontaneous abortions. Endocr Connect (2022) 11(4):e210600. doi: 10.1530/EC-21-0600
28. Geng X, Chen Y, Li S, Wang W, Wu W, Sun C, et al. Systematic review and meta-analysis on the influence of thyroid dysfunction in early pregnancy on pregnancy outcomes under ultrasound guidance. Ann Palliat Med (2022) 11(3):1001–16. doi: 10.21037/apm-22-47
29. Nazarpour S, Ramezani Tehrani F, Simbar M, Tohidi M, Alavi Majd H, Azizi F. Effects of levothyroxine treatment on pregnancy outcomes in pregnant women with autoimmune thyroid disease. Eur J Endocrinol (2017) 176(2):253–65. doi: 10.1530/EJE-16-0548
30. Fliers E, Kalsbeek A, Boelen A. Beyond the fixed setpoint of the hypothalamus-pituitary-thyroid axis. Eur J Endocrinol (2014) 171(5):R197–208. doi: 10.1530/EJE-14-0285
31. Fernando- Ruocco J, Gallego M, Rodriguez-de-Yeure A, Zayas-Arrabel J, Echeazarra L, Alquiza A, et al. High thyrotropin is critical for cardiac electrical remodelling and arrhythmia vulnerability in hypothyroidism. Thyroid (2019) 29:934–45. doi: 10.1098/thy.2018.0709
32. Van der Deure WM, Uitterlinden AG, Hofman A, Rivadeneira F, Pols HA, Peeters RP, et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: The Rotterdam study. Clin Endocrinol (Oxf) (2008) 68(2):175–81. doi: 10.1111/j.1365-2265.2007
33. Pekonen F, Alfthan H, Stenman UH, Ylikorkala O. Human chorionic gonadotropin (hCG) and thyroid function in early human pregnancy: Circadian variation and evidence for intrinsic thyrotropic activity of hCG. J Clin Endocrinol Metab (1988) 66(4):853–6. doi: 10.1210/jcem-66-4-853
34. Korevaar TIM, de Rijke YB, Chaker L, Medici M, Jaddoe VWV, Steegers EAP, et al. Stimulation of thyroid function by human chorionic gonadotropin during pregnancy: A risk factor for thyroid disease and a mechanism for known risk factors. Thyroid (2017) 27(3):440–50. doi: 10.1089/thy.2016.0527
35. Sun R, Xia J. The reference intervals of thyroid hormones for pregnant women in zhejiang province. Lab Med (2018) 49(1):5–10. doi: 10.1093/labmed/lmx070
36. Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, et al. Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol (2009) 200(3):260.e1–6. doi: 10.1016/j.ajog.2008.10.042
37. Dosiou C, Medici M. Isolated maternal hypothyroxinemia during pregnancy: knowns and unknowns. Eur J Endocrinol (2017) 176:821–38. doi: 10.1530/EJE-16-0354
38. Grün JP, Meuris S, De Nayer P, Glinoer D. The thyrotrophic role of human chorionic gonadotrophin (hCG) in the early stages of twin (versus single) pregnancies. Clin Endocrinol (Oxf) (1997) 46(6):719–25. doi: 10.1046/j.1365-2265.1997.2011011.x
39. de Medeiros SF, Norman RJ. Human choriogonadotrophin protein core and sugar branches heterogeneity: Basic and clinical insights. Hum Reprod Update (2009) 15(1):69–95. doi: 10.1093/humupd/dmn036
40. Bariktarovic M, Korevaar TIM, Jaddoe VWV, de Rijke YB, Peeters RP, Steegers EAP. Human chorionic gonadotropin and risk of pre-eclampsia: Prospective population-based cohort study. Ultrasound Obstet Gynecol (2019) 54(4):477–83. doi: 10.1002/uog.20256
41. Åsvold BO, Vatten LJ, Tanbo TG, Eskild A. Concentrations of human chorionic gonadotrophin in very early pregnancy and subsequent pre-eclampsia: A cohort study. Hum Reprod (2014) 29(6):1153–60. doi: 10.1093/humrep/deu068
42. Yang Y, Guo T, Fu J, Kuang J, Wang Y, Zhang Y, et al. Preconception thyrotropin levels and risk of adverse pregnancy outcomes in Chinese women aged 20 to 49 years. JAMA Netw Open (2021) 4(4):e215723. doi: 10.1001/jamanetworkopen.2021.5723
43. Korevaar TIM, Steegers EAP, Pop VJ, Broeren MA, Chaker L, de Rijke YB, et al. Thyroid autoimmunity impairs the thyroidal response to human chorionic gonadotropin: Two population-based prospective cohort studies. J Clin Endocrinol Metab (2017) 102, Issue 1:69–77. doi: 10.1210/jc.2016-2942
44. Brander L, Als C, Buess H, Haldimann F, Harder M, Hänggi W, et al. Urinary iodine concentration during pregnancy in an area of unstable dietary iodine intake in Switzerland. J Endocrinol Invest (2003) 26(5):389–96. doi: 10.1007/BF03345192
45. Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis (2013) 20(3):209–14. doi: 10.1053/j.ackd.2013.01.012
46. Rotondi M, Amato G, Biondi B, Mazziotti G, Del Boone A, Rotonda Nicchio M, et al. Parity as a thyroid-size-determining factor in areas with moderate iodine deficiency. J Clin Endocrinol Metab (2000) 85(12):4534–7. doi: 10.1012/jcem.85.12.7002
47. Glinoer D, De Nayer P, Delange F, Lemone M, Toppet V, Spehl M, et al. A randomized trial for the treatment of mild iodine deficiency during pregnancy: Maternal and neonatal effects. J Clin Endocrinol Metab (1995) 80(1):258–69. doi: 10.1210/jcem.80.1.7829623
48. Berbel P, Mestre JL, Santamaría A, Palazón I, Franco A, Graells M, et al. Delayed neurobehavioral development in children born to pregnant women with mild hypothyroxinemia during the first month of gestation: The importance of early iodine supplementation. Thyroid (2009) 19(5):511–9. doi: 10.1089/thy.2008.0341
49. Eastman CJ, Ma G, Li M. Optimal assessment and quantification of iodine nutrition in pregnancy and lactation: Laboratory and clinical methods, controversies and future directions. Nutrients (2019) 11(10):2378. doi: 10.3390/nu11102378
50. Moleti M, Trimarchi F, Tortorella G, Candia Longo A, Giorgianni G, Sturniolo G, et al. Effects of maternal iodine nutrition and thyroid status on cognitive development in offspring: A pilot study. Thyroid (2016) 26(2):296–305. doi: 10.1089/thy.2015.0336
51. Makepeace AE, Bremner AP, O'Leary P, Leedman PJ, Feddema P, Michelangeli V, et al. Significant inverse relationship between serum free T4 concentration and body mass index in euthyroid subjects: Differences between smokers and nonsmokers. Clin Endocrinol (Oxf) (2008) 69(4):648–52. doi: 10.1111/j.1365-2265.2008.03239.x
52. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab (2003) 88(8):3731–7. doi: 10.1210/jc.2003-030039
53. Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer PH, Pijl H, et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid (2001) 11(2):153–60. doi: 10.1089/105072501300042820
54. Chan S, Kilby MD. Thyroid hormone and central nervous system development. J Endocrinol (2000) 165(1):1–8. doi: 10.1677/joe.0.1650001
55. Ausó E, Lavado-Autric R, Cuevas E, Del Rey FE, Morreale De Escobar G, Berbel P. A moderate and transient deficiency of maternal thyroid function at the beginning of fetal neocorticogenesis alters neuronal migration. Endocrinology (2004) 145(9):4037–47. doi: 10.1210/en.2004-0274
56. Cooper DS, Pearce EN. Subclinical hypothyroidism and hypothyroxinemia in pregnancy - still no answers. N Engl J Med (2017) 376(9):876–7. doi: 10.1056/NEJMe1615312
57. Polk DH, Reviczky A, Lam RW, Fisher DA. Thyrotropin-releasing hormone in ovine fetus: ontogeny and effect of thyroid hormone. Am J Physiol (1991) 260(1 Pt 1):E53–8. doi: 10.1152/ajpendo.1991.260.1.E53
58. Contempré B, Jauniaux E, Calvo R, Jurkovic D, Campbell S, de Escobar GM. Detection of thyroid hormones in human embryonic cavities during the first trimester of pregnancy. J Clin Endocrinol Metab (1993) 77(6):1719–22. doi: 10.1210/jcem.77.6.8263162
59. Peng S, Li C, Xie X, Zhang X, Wang D, Lu X, et al. Divergence of iodine and thyroid hormones in the fetal and maternal parts of human-term placenta. Biol Trace Elem Res (2020) 195(1):27–38. doi: 10.1007/s12011-019-01834-z
60. Sheehan MT. Biochemical testing of the thyroid: TSH is the best and, oftentimes, only test needed - a review for primary care. Clin Med Res (2016) 14(2):83–92. doi: 10.3121/cmr.2016.1309
61. Fitzgerald SP, Falhammar H. Redefinition of successful treatment of patients with hypothyroidism: is TSH the best marker of euthyroidism? Front Endocrinol (2022) 13:920854. doi: 10.3389/fendo.2022.920854
62. Fitzgerald SP, Bean NG. Thyroid stimulating hormone (TSH) autoregulation reduces variation in the TSH response to thyroid hormones. Temperature (2018) 5:380–9. doi: 10.1080/23328940.2018.1513110
63. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. The role of functional thyroid capacity in pituitary thyroid feedback regulation. Eur J Clin Invest (2018) 48:e13003. doi: 10.1111/eci.13003
64. The Consortium on Thyroid and Pregnancy—Study Group on Preterm Birth. Association of thyroid function test abnormalities and thyroid autoimmunity with preterm birth: A systematic review and meta-analysis. JAMA (2019) 322(7):632–41. doi: 10.1001/jama.2019.10931
65. Derakhshan A, Peeters RP, Taylor PN, Bliddal S, Carty DM, Meems M, et al. Association of maternal thyroid function with birthweight: A systemic review and individual participant data meta-analysis. Lancet Diabetes Endocrinol (2020) 8(6):501–10. doi: 10.1016/S22213-8587(20)30061-9
66. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol (2006) 107(2 Pt 1):337–41. doi: 10.1097/01.AOG.0000197991.64246.9a
67. Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP. The relationship between TSH and free T4in a large population is complex and nonlinear and differs by age and sex. J Clin Endocrinol Metab (2013) 98(7):2936–43. doi: 10.1210/jc.2012-4223
68. Korevaar TIM, Schalekamp-Timmermans S, de Rijke YB, Visser WE, Visser W, de Muinck Keizer-Schrama SMPF, et al. Hypothyroxinemia and TPO-antibody positivity are risk factors for premature delivery: The generation r study. J Clin Endocrinol Metab (2013) 98:4382–90. doi: 10.1210/jc.2013-2855
69. Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH. Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death. Thyroid (2010) 20(9):989–93. doi: 10.1089/thy.2010.0058
70. Knight BA, Shields BM, Hattersley AT, Vaidya B. Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters. Eur J Endocrinol (2016) 174(1):51–7. doi: 10.1530/EJE-15-0866
71. Medici M, Korevaar TI, Schalekamp-Timmermans S, Gaillard R, de Rijke YB, Visser WE, et al. Maternal early-pregnancy thyroid function is associated with subsequent hypertensive disorders of pregnancy: The generation r study. J Clin Endocrinol Metab (2014) 99(12):E2591–8. doi: 10.1210/jc.2014-1505
72. Pramanik S, Mukhopadhyay P, Ghosh S. Total T4 rise in pregnancy: A relook? Thyroid Res (2020) 13:14. doi: 10.1186/s13044-020-00088-5
73. Napso T, Yong H, Lopez-Tello J, Sferruzzi-Perri A. The role of placental hormones in mediating maternal adaptions to support pregnancy and lactation. Front Physiol (2018). doi: 10.3389/fphys.2018.01091
74. Mendel CM. The free hormone hypothesis: A physiologically based mathematical model. Endoc Rev (1989) 10(3):232–74. doi: 10.1210/EDRV-10-3-232
75. Bikle DD, Schwartz J. Vitamin d binding protein, total and free vitamin d levels in different physiological and pathophysiological conditions. Front Endocrinol (2019). doi: 10.3389/fendo.2019.00317
76. Jostel A, Ryder WDJ, Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: Definition and evaluation of the TSH index. Clin Endocrinol (Oxf) (2009) 71:529–34. doi: 10.1111/j.1365-2265.2009
77. Blumenthal N, Eastman C. Beneficial effects on pregnancy outcomes of thyroid hormone replacement for subclinical hypothyroidism. J Thyroid Res (2017) 2017:4601365. doi: 10.1155/2017/4601365
Keywords: pregnancy, thyroid physiology, FT4, TSH, thyroid state
Citation: Fitzgerald SP, Bean NG, Fitzgerald SP and Falhammar H (2022) The application of new concepts of the assessment of the thyroid state to pregnant women. Front. Endocrinol. 13:987397. doi: 10.3389/fendo.2022.987397
Received: 06 July 2022; Accepted: 25 July 2022;
Published: 16 August 2022.
Edited by:
Creswell John Eastman, The University of Sydney, AustraliaReviewed by:
Mario Rotondi, University of Pavia, ItalyMiriam Oliveira Ribeiro, Mackenzie Presbyterian University, Brazil
Copyright © 2022 Fitzgerald, Bean, Fitzgerald and Falhammar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stephen P. Fitzgerald, stephen.fitzgerald2@sa.gov.au
†ORCID: Stephen P. Fitzgerald, orcid.org/0000-0002-9755-2316
Nigel G. Bean, orcid.org/0000-0002-5351-3104
Samuel P. Fitzgerald, orcid.org/0000-0002-9797-5722
Henrik Falhammar, orcid.org/0000-0002-5622-6987